Getting local: focusing on communities to achieve greater impact in the next phase of the HIV response

Ade O Fakoya1,2*, Mark R Dybul3,4* and Peter Sands1,5

*Corresponding author: Ade O Fakoya, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland. Tel: +41587911832. (ade.fakoya@theglobalfund.org)

*These authors have contributed equally to the work.

© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Despite numerous achievements in addressing HIV epidemics worldwide, there is still much more that needs to be done to control HIV as a public health threat [1]. As such, the world is at a critical juncture in the HIV response. Decelerating the response now would reverse the enormous gains achieved so far [2].

Many countries are not on track to reach the ambitious treatment and prevention goals set by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and others. Although several national programmes are making progress when statistics are rolled up to the national level [3], too often at district and local levels, many of the key and vulnerable populations are being left behind. Some groups remain disproportionately affected by HIV and are conspicuously absent or under-represented in HIV services. Adolescent girls and young women, sex workers, heterosexual men in high HIV prevalence setting, men who have sex with men, transgender people and incarcerated individuals continue to be underserved by HIV prevention and treatment programmes [4]. Recently, there has been increased attention on the low uptake of HIV testing and treatment in heterosexual men [5] and the very low percentage of adolescents who know their status. In one study of 16 African countries, men were up to 70% less likely to know their status compared to women. The figure for adolescents aged 16 to 19 years was 40% compared to the 30- to 39-year-old age group [6].

The rapid scaling up of treatment has led to over 20 million people receiving life-saving HIV medication; however, the quality of services has been inconsistent across different settings. In some places, a staggering two-fifths (40%) of people on therapy are lost to follow-up [7,8]. Additionally, due to variable levels of viral suppression (caused by a shortened duration of anti-retroviral therapy (ART) access and poor ART adherence at the individual level), the number of persons acquiring primary HIV-resistant virus is increasing [9,10]. Even where coverage of ART is high, the impact on preventing new infections has so far failed to reach levels that had been predicted, and incidence rates remain too high for long-term epidemic control [11]. Therefore, there is an urgent need for new approaches and tools to tackle stubbornly persistent and alarmingly high incidence rates in the above-mentioned groups.

As the HIV response becomes increasingly medicalized, engagement of, and funding for, community-level interventions are threatened. There is little hope of succeeding in reaching the most vulnerable without greater community leadership.

Finally, there is insufficient focus on reducing the cost of delivery, including greater impact for investment. There is a growing body of evidence on how to maximize impact (including through differentiated service delivery) but the disconnect from country-level decision-making, community engagement and delivery make significant progress challenging. Significant cost savings could open fiscal space to help ensure key components of an effective response receive more funding [12].

Increasingly, countries are focusing on several critical areas to drive the responses towards greater impact and greater sustainability by aligning services to the identified needs of individuals and communities. Ensuring that there is a fully funded response with efficient utilization of domestic and external resources is fundamental [13]. We would suggest four other critical elements: (a) adapting services based on community involvement and demand, so, called human-centred design; (b) “taking AIDS out of isolation” by addressing the wider determinants of health and social wellbeing including gender norms, stigma and the economic costs of accessing health services, including user fees [2]; (c) using data to identify and map where most infections are occurring, and (while respecting equity) targeting high-quality differentiated, comprehensive prevention and treatment interventions to specific localities; and (d) capacitating communities to work across all levels of the health response, enabling them to utilize and respond to evidence and achieve impact [14].

Involving communities in the design, monitoring and evaluation of services takes time and resources. But tailoring...
services to individual needs is one aspect of service quality [15] and the Lancet Global Health Commission on High-Quality Health Systems in the Sustainable Development Goals Era report has recently highlighted patient experience as a key component of quality health services [16]. Often individual barriers to optimal engagement and access to care such as mental health problems, substance use, violence and stigma may not immediately be apparent [17]. There are many examples within the literature where services have been adapted, or differentiated to tailor to specifically identified needs or issue, from developing community-based strategies to improve men’s access to HIV testing and treatment [18] to tailoring clinic times and environments to improve accessibility for adolescents [19]. Although it is early in the process, the human-centred design methodology has been used to improve several aspects of service delivery, including access to pre-exposure prophylaxis [20] and services for adolescents [21].

Considering HIV within a wider context has multiple facets. These include integrating HIV into broader health services to improve HIV and non-HIV-related health outcomes; exploring the synergies and co-dependencies of HIV investments on health systems; and examining the benefits of strong health and community systems to reach HIV and other development goals [22].

The focus on critical populations and locations is not new [23,24], and many countries and cities within countries are adopting this focus [25,26]. Already more than half the world’s population live in cities, which are uniquely positioned to lead the response towards achieving the UNAIDS treatment and prevention targets. Cities may also be HIV hotspots, and people living in or near a hotspot have a much higher risk of acquiring HIV infection compared to those living outside of the hotspot [27].

By adding emphasis on delivering services aligned with community-identified needs, and by linking the outcomes of this human-centred design process to regional and national policy makers and high-level decision makers, we can provide a model which has potential to drive a more effective response. Several countries are now exploring these methodologies.

One final aspect of service adaptation to address the needs of particular groups is the issue of scale. It is not enough that services cater for a limited number of clients; impact can only be feasibly achieved if we move from demonstration projects to full coverage at scale. This can be achieved [19], but often it is a critical limitation of implementing these approaches which must be addressed.

Achieving a greater impact in the next phase of the HIV response requires an improvement in the quality and integration of services to make the services align to the identified needs of communities.

AUTHORS’ AFFILIATIONS

1 The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland;
2 Department of Infection and Population Health, University College London, UK;
3 Center for Global Health Practice and Impact, Georgetown University School of Medicine, Washington, USA;
4 Joep Lange Institute, Amsterdam, the Netherlands;
5 Harvard Global Health Institute, Cambridge, USA

COMPETING INTERESTS

AF and PS report no conflicts of interest.

MD received a research grant from the Bill and Melinda Gates Foundation to support work on human-centred design.

AUTHORS’ CONTRIBUTIONS

All authors contributed equally to this work.

ACKNOWLEDGEMENTS

We thank all those involved in this work and developing this manuscript including Aji-Mallen Sanneh, Ibidun Fakoya and Seth Faison.

REFERENCES

1. UNAIDS Fast- UNAIDS AIDS epidemic by 2030, 2014[cited 2019 July 5]. Available at: http://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf
2. Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, et al. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission. The Lancet. 2018;392(10144):312–58.
3. Global AIDS. Update 2018: miles to go: closing gaps, breaking barriers, righting injustices. Geneva: Joint United Nations Programme on HIV; AIDS; 2018.
4. Shannon K, Crago AL, Baral SD, Bekker LG, Kerrigan D, Decker MR, et al. The global response and unmet actions for HIV and sex workers. Lancet. 2018;392(10148):698–710.
5. Adeeye AO, Stirrat MJ, Burns DN. Engaging men in HIV treatment and prevention. Lancet. 2018;392(10162):2334–5.
6. Stavetski S, Croft TN, Kampa KT, Head SK. Reaching the ‘First 90%’: gaps in coverage of HIV testing among people living with HIV in 16 African countries. PLoS ONE. 2017;12(10):e0186316.
7. Haas AD, Zanievski E, Anderegg N, Ford N, Fox MP, Vinkoor M, et al. Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. Journal of the International AIDS Society. 2018;21(2):e25084.
8. Bernard C, Balestre E, Coffie PA, Eholie SP, Messou E, Kwaghe V, et al. Aging with HIV: what effect on mortality and loss to follow-up in the course of antiretroviral therapy? The iDeA West Africa Cohort Collaboration. HIV/AIDS (Auckland, NZ). 2018;10:239.
9. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Forero LA, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346–55.
10. Ngo-Giang-Huong N, Aghokeng AF. HIV drug resistance in resource-limited countries: threat for HIV elimination. E Clinical Medicine. 2019;1(9):3–4.
11. Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. The Lancet HIV. 2018;5(3):e116–25.
12. Kandasami S, Shobhiye H, Fakoya A, Asimwwe S, Inmah M, Etkoilt M, et al. Can changes in service delivery models improve program quality and efficiency? A closer look at HIV programs in Kenya and Uganda. J Acquir Immune Defic Syndr. 2019 Jul 05. Available at: https://journals.lww.com/ids/Abstract/publishahead/Can_changes_in_service_delivery_models_improve.96387.aspx
13. Global Fund investment case summary. Global Fund, 2019[cited 2019 Jul 5]. Available at: https://www.theglobalfund.org/en/news/2019-01-11-global-fund-announces-us14-billion-target-to-step-up-the-fight-against-aids-tb-and-malaria/
14. Stronger together: From health and community systems to systems for health UNAIDS. 2016[cited 2019 Jul 08] Available at: https://www.unaids.org/en/resources/documents/2016/JC2788_stronger_together
15. WHO technical brief. Maintaining and improving quality of care within HIV. Clinical Services WHO. 2019.2.
16. Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. The Lancet Global Health. 2018;6(11):e1196–252.
17. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy? The IeDEA West Africa Cohort Collaboration. HIV/AIDS (Auckland, NZ). 2018;10:239.
18. Bernard C, Balestre E, Coffie PA, Eholie SP, Messou E, Kwaghe V, et al. Aging with HIV: what effect on mortality and loss to follow-up in the course of antiretroviral therapy? The IeDEA West Africa Cohort Collaboration. HIV/AIDS (Auckland, NZ). 2018;10:239.
19. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Forero LA, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346–55.
20. Ngo-Giang-Huong N, Aghokeng AF. HIV drug resistance in resource-limited countries: threat for HIV elimination. E Clinical Medicine. 2019;1(9):3–4.
21. Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. The Lancet HIV. 2018;5(3):e116–25.
22. Kandasami S, Shobhiye H, Fakoya A, Asimwwe S, Inmah M, Etkoilt M, et al. Can changes in service delivery models improve program quality and efficiency? A closer look at HIV programs in Kenya and Uganda. J Acquir Immune Defic Syndr. 2019 Jul 05. Available at: https://journals.lww.com/ids/Abstract/publishahead/Can_changes_in_service_delivery_models_improve.96387.aspx
23. Global Fund investment case summary. Global Fund, 2019[cited 2019 Jul 5]. Available at: https://www.theglobalfund.org/en/news/2019-01-11-global-fund-announces-us14-billion-target-to-step-up-the-fight-against-aids-tb-and-malaria/
24. Stronger together: From health and community systems to systems for health UNAIDS. 2016[cited 2019 Jul 08] Available at: https://www.unaids.org/en/resources/documents/2016/JC2788_stronger_together
25. WHO technical brief. Maintaining and improving quality of care within HIV. Clinical Services WHO. 2019.2.
26. Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. The Lancet Global Health. 2018;6(11):e1196–252.
27. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183.
28. Sharma M, Barnabas RV, Celum C. Community-based strategies to strengthen men’s engagement in the HIV care cascade in sub-Saharan Africa. PLoS Med. 2017;14(4):e1002262.
29. Willis N, Napei T, Armstrong A, Jackson H, Apollo T, Mushavi A, et al. Zvandiri—Bringing a Differentiated Service Delivery Program to Scale for Children, Adolescents, and Young People in Zimbabwe. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2018;15(7):S115–23.
20. Sharma S, Bell J, Levy M, Reast J, Malone S, Hasen N, et al. Individual, social and structural barriers to HIV testing and treatment among high-risk young men in South Africa. Abstract South Africa AIDS conference Durban 11-14th June 2019.

21. “Where are the Men?” Emerging Design Insights and Opportunities for Reaching Young Men in The Battle Against HIV. [cited 2019 Jul 5]. Available at: https://www.dalberg.com/our-ideas/emerging-design-insights-and-opportunities-for-reaching-young-men-in-the-battle-against-hiv

22. Sands P. HIV: from exceptionalism to endgame. Lancet. 2018;392(10144):261–2.

23. Jones A, Cremin I, Abdullah F, Idoko J, Cherutich P, Kilonzo N, et al. Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. Lancet. 2014;384(9939):272–9.

24. Anderson SJ, Cherutich P, Kilonzo N, Cremin I, Fecht D, Kimanga D, et al. Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. Lancet. 2014;384(9939):249–56.

25. Joint United Nations Programme on HIV/AIDS (UNAIDS). On the Fast-Track to end AIDS by 2030: Focus on location and population. Geneva: UNAIDS; 2015. 2030 p.

26. Granich R, Williams B, Montaner J, Zuniga JM. 90-90-90 and ending AIDS: necessary and feasible. Lancet. 2017;390(10092):341–3.

27. Cuadros DF, Gráf T, de Oliveira T, Bärmighausen T, Tanser F. Assessing the role of geographical HIV hot-spots in the spread of the epidemic. Conference on Retroviruses and Opportunistic Infections (CROI), Boston (MA), 4–7 March 2018.